Form 4: Assembly Biosciences Director William Ringo Granted 3,500 Stock Options

Assembly Biosciences, Inc. Director William R. Ringo was granted 3,500 stock options with an exercise price of $15.81, vesting upon the earlier of June 5, 2026, or the company's 2026 annual meeting.

Summary

• William R. Ringo, a Director of Assembly Biosciences, Inc. (ASMB), was granted 3,500 stock options.
• The options have an exercise price of $15.81 per share.
• These options will vest upon the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on continuous service.
• The expiration date for these stock options is June 5, 2035.
• Following this transaction, Mr. Ringo beneficially owns 3,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns management interests with shareholders, but it is a routine compensation matter and not indicative of significant operational or financial news.

Positives

• The grant of stock options to Director William R. Ringo aligns his interests with those of shareholders, incentivizing long-term value creation.
• This is a standard form of compensation for directors, indicating continuity in corporate governance practices.

Negatives

• No immediate negative financial implications are apparent from this routine compensation grant.

Risks

• The value of the stock options is subject to the future market price of Assembly Biosciences' common stock, meaning they could become worthless if the stock price falls below the exercise price of $15.81.
• Vesting is contingent on continuous service, meaning the options could be forfeited if the director's service terminates before the vesting date.

Future Outlook

The grant of stock options with a future vesting schedule implies an expectation of continued service from Director William R. Ringo and aligns his long-term incentives with the company's performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term shareholder value.

Comparison to Industry Standards

• This type of equity grant is a standard compensation mechanism for directors in publicly traded biotechnology companies.
• While specific comparable companies or projects are not detailed in this filing, the structure of the option grant (vesting over time, specific exercise price) is consistent with typical industry practices for incentivizing long-term commitment and performance.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The granted stock options will vest upon the earlier of June 5, 2026, or the date of Assembly Biosciences' 2026 annual meeting of stockholders, assuming continuous service.

Key Dates

Keywords

Assembly Biosciences, ASMB, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Corporate Governance